These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11685727)

  • 21. Single-agent chemotherapy with docetaxel significantly reduces PSA levels in patients with high-grade localized prostate cancers.
    Berger AP; Niescher M; Fischer-Colbrie R; Pelzer A; Bartsch G; Horninger W
    Urol Int; 2004; 73(2):110-2. PubMed ID: 15331892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.
    Bergstrom CP; Ruffell B; Ho CM; Higano CS; Ellis WJ; Garzotto M; Beer TM; Graff JN
    Anticancer Drugs; 2017 Jan; 28(1):120-126. PubMed ID: 27669423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
    Womble PR; VanVeldhuizen PJ; Nisbet AA; Reed GA; Thrasher JB; Holzbeierlein JM
    J Urol; 2011 Sep; 186(3):882-7. PubMed ID: 21791342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel and docetaxel in prostate cancer.
    Obasaju C; Hudes GR
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
    Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Docetaxel in prostate cancer.
    Small EJ
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S17-20. PubMed ID: 11340899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study.
    Nosov A; Reva S; Petrov S; Mamijev E; Novikov R; Veliev E; Imkamp F; Tolkach Y; Moiseenko V
    Prostate; 2016 Nov; 76(15):1345-52. PubMed ID: 26864707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer.
    Narita S; Tsuchiya N; Kumazawa T; Maita S; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Nanjyo H; Habuchi T
    World J Surg Oncol; 2012 Jan; 10():1. PubMed ID: 22214417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
    Oh WK; Kantoff PW
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
    Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
    Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docetaxel (taxotere) in the treatment of prostate cancer.
    Beer TM; El-Geneidi M; Eilers KM
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):261-8. PubMed ID: 12820771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
    Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer.
    Sella A; Zisman A; Kovel S; Yarom N; Leibovici D; Lindner A
    Urology; 2008 Feb; 71(2):323-7. PubMed ID: 18308112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer.
    Sitka Copur M; Ledakis P; Lynch J; Hauke R; Tarantolo S; Bolton M; Norvell M; Muhvic J; Hake L; Wendt J
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):16-21. PubMed ID: 11685724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.
    Dreicer R; Magi-Galluzzi C; Zhou M; Rothaermel J; Reuther A; Ulchaker J; Zippe C; Fergany A; Klein EA
    Urology; 2004 Jun; 63(6):1138-42. PubMed ID: 15183967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.
    Galsky MD; Xie W; Nakabayashi M; Ross RW; Fennessy FM; Tempany CM; Choueiri TK; Khine K; Kantoff PW; Taplin ME; Oh WK
    Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):266-70. PubMed ID: 23712318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
    Kibel AS; Rosenbaum E; Kattan MW; Picus J; Dreicer R; Klein EA; Chatta GS; Nelson JB; DiPaola RS; Roth BJ; Cookson MS; Wilding G; Jarrard DF; Beer TM; Ryan CW; Petrylak DP; Benson MC; Partin AW; Garrett-Mayer E; Eisenberger MA
    J Urol; 2007 May; 177(5):1777-81. PubMed ID: 17437819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer.
    Garzotto M; Myrthue A; Higano CS; Beer TM
    Urol Oncol; 2006; 24(3):254-9. PubMed ID: 16678060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
    McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
    Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.